ONC earnings analysis
What we found in ONC's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
BeOne delivered a strong Q2: revenue grew 29.6% to $1.705 billion, diluted GAAP EPS increased to $2.05 per ADS from $0.84, and operating income rose to $325.0 million from $87.9 million. Growth was overwhelmingly led by $1.248 billion of BRUKINSA revenue, while product gross margin improved to 89.6% and free cash flow reached $435.3 million. Liquidity improved to $5.281 billion, although investors should monitor the $59.0 million China tax-audit expense, $1.073 billion debt balance, pharmaceutical tariff developments, and ongoing AbbVie litigation.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue growth remained near 30%
- Q2 revenue rose $389.8 million, or 29.6% year over year, to $1.705 billion. Revenue also increased sequentially from an implied $1.513 billion in Q1, based on reported six-month revenue of $3.219 billion.
- Product gross margin expanded 220 bps
- Gross margin on product sales expanded 220 basis points year over year to 89.6%, from 87.4%, driven by a greater global BRUKINSA mix and production productivity improvements for BRUKINSA and TEVIMBRA.
- Operating leverage sharply lifted earnings
- Operating income increased $237.2 million to $325.0 million from $87.9 million, lifting operating margin to approximately 19.1% from approximately 6.7%. Q2 diluted GAAP EPS was $2.05 per ADS, versus $0.84 a year earlier.
- BRUKINSA remained the core growth driver
- BRUKINSA generated $1.248 billion of revenue, up 31.4%; U.S. sales were $892.5 million (+30.5%) and Europe sales were $195.6 million (+30.0%). Management attributed the U.S. performance primarily to robust demand growth and cited continued European share gains.
- Cash conversion and capex intensity improved
- Q2 operating cash flow rose to $462.8 million from $263.6 million, while free cash flow nearly doubled to $435.3 million from $219.8 million. Capex was $27.5 million, or roughly 1.6% of revenue, versus $43.8 million a year ago.
- Liquidity strengthened despite modest debt increase
- Cash, cash equivalents and restricted cash increased $671.0 million from December 31 to $5.281 billion at June 30, while total debt increased $53.9 million to $1.073 billion. Management said this liquidity supports the operating plan and long-term investments for at least 12 months.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- China tax settlement raised tax expense
- A China tax-audit settlement produced approximately $59.0 million of discrete Q2 tax expense; the company paid approximately RMB446 million, including tax and late-payment interest, in July 2026. Gross unrecognized tax benefits were $26.0 million at June 30, leaving exposure to different outcomes from ongoing audits.
- Floating-rate debt creates rate sensitivity
- The company had $1.1 billion of floating-rate debt at June 30, and a 100-basis-point rate increase would raise annual pre-tax interest expense by approximately $10.9 million. It expects to repay $201.1 million of bank loans over the next 12 months.
- New pharmaceutical tariff exposure
- The updated international-operations risk notes U.S. tariffs of 10% to 100% on certain patented pharmaceutical articles and associated ingredients beginning in September 2026. The scope and applicability remain uncertain, but could raise supply-chain costs or affect commercial viability.
- AbbVie trade-secret litigation continues
- AbbVie's trade-secret litigation over the BTK degrader program remains ongoing after the court denied BeOne's motion to dismiss on May 12, 2026. The complaint seeks an unspecified amount of monetary damages and no trial date has been scheduled.
- Two product lines declined year over year
- KYPROLIS revenue declined $4.3 million, or 22.0%, to $15.1 million, while POBEVCY declined $1.6 million, or 14.3%, to $9.6 million. These declines partially offset growth in BRUKINSA, TEVIMBRA, and Amgen products.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $2.05
- Gross margin
- 89.6%
- Operating margin
- 19.1%
- Segment
- BRUKINSA revenue: $1.248 billion, +31.4% year over year
- Segment
- TEVIMBRA revenue: $228.5 million, +18.1% year over year
- Segment
- XGEVA revenue: $104.5 million, +28.5% year over year
- Segment
- BLINCYTO revenue: $36.5 million, +42.8% year over year
- Segment
- KYPROLIS revenue: $15.1 million, -22.0% year over year
- Segment
- POBEVCY revenue: $9.6 million, -14.3% year over year
- Segment
- Other product revenue: $37.8 million, +78.8% year over year
What they said about what is next.
The 10-Q provides no quantitative revenue or EPS guidance. Management expects operating cash flow and existing cash to fund operating expenses and planned long-term investments for at least the next 12 months, and expects to repay approximately $201.1 million of bank loans in that period.
The filing reads better than the one before it.
What came before.
- 10-Q · May 6, 2026
- BeOne Medicines Ltd. reported strong Q1 2026 financial results, with total revenue of $1.51 billion, a 35% increase year-over-year, driven largely by successful sales of BRUKINSA, which saw a 38% revenue growth. The…
- 10-K · February 26, 2026
- BeOne Medicines reported strong 2025 results with total revenue of approximately $5.3 billion (up ~40.2% year-over-year), GAAP net income of $286.9 million, and positive free cash flow of $941.7 million. Commercial…
- 10-Q · November 6, 2025
- BeOne Medicines (filed as BeOne/previously BeiGene) reported a strong quarter with total revenues of $1,412,284 (in thousands) vs $1,001,599 in the year-ago quarter and returned to profitability with net income of…
- 10-Q · May 7, 2025
- BeiGene reported strong Q1 results with total revenues of $1,117,279 (amounts in thousands) versus $751,652 in Q1 2024, driven by higher product and collaboration revenue. Gross profit expanded to $952,277 (thousands)…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ONC makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever